Exclusive: PsiOxus Therapeutics may look at IPO in 2017

4 November 2016

Immuno-oncology company PsiOxus Therapeutics may opt for an initial public offering in 2017, though the company is not looking to go public anytime sooner, chief executive John Beadle told The Pharma Letter in an exclusive interview.

“If it is on the horizon it may be in 2017,” the Dr Beadle said, when asked about the IPO plans.

In May 2015, Neil Woodford's new $1.2 billion fund and GlaxoSmithKline's (LSE: GSK) venture capital unit contributed to a $39 million Series C round in PsiOxus. The funds were allocated to the company’s study of oncolytic virus, together with a checkpoint inhibitor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK